A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc
SciELO - Brazil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection
Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) | BMJ Open
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. | Semantic Scholar
Percent free prostate‐specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower - Walz - 2008 - Cancer - Wiley Online Library
Urology PSA Calculator App | Lumos Educational App Store
PSA Calculator - in English 1.0 Android APK Free Download – APKTurbo
Prostate cancer screening in Europe and Asia - ScienceDirect
Prostate Cancer Risk Calculator - ProstateRisk.ca / Rezum For BPH
PSA calculator courtesy of Dow PSTC Baltimore - Process & Control
How Much Do Prostate Cancer Tests Cost Without Insurance? - GoodRx
Prostate‐specific antigen: Current status - Brawer - 1999 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Prostate Volume Calculator | BackTable Practice Tools
Tool helps predict who will respond best to targeted prostate cancer therapy | UCLA
Metastatic Prostate Cancer: The PSA Screening Debate - Life Extension
PSA Density Calculator
Urology PSA Calculator on the App Store
Table 4 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar
Free PSA: Test, results, and prostate cancer
SciELO - Brazil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports